Skip to main content
Top
Published in: Vascular Cell 1/2013

Open Access 01-12-2013 | Research

Correlation of tumor-associated macrophages and clinicopathological factors in Wilms tumor

Authors: Peter Liou, Leah Bader, Antai Wang, Darrell Yamashiro, Jessica J Kandel

Published in: Vascular Cell | Issue 1/2013

Login to get access

Abstract

Background/purpose

Despite high long-term survival rates in patients with Wilms tumor, there is a need to develop better prognostic biomarkers in order to maximize cure while avoiding treatment-associated morbidities. Tumor-associated macrophages have been recently associated with poorer prognosis and increased disease progression in a number of adult cancers. We investigated the relationship between macrophages and clinicopathological fators in this pediatric solid tumor.

Methods

Tissue microarray sections of 124 Wilms tumor cases obtained from the Cooperative Human Tissue Network were stained with CD68, a macrophage marker using standard immunohistochemical techniques and quantified using digital image processing techniques. Macrophage densities were correlated by tumor stage, and survival analyses were conducted with available clinical data. Immunohistochemistry was performed on 25 additional Wilms tumor cases obtained from the tumor bank at Columbia University Medical Center and correlated with presence of tumor microvascular invasion.

Results

Mean macrophage count densities in stage IV tumors were significantly greater than densities in stage I and III tumors (p=.021, .036). Although the overall and disease-free survival did not differ between high and low macrophage presence groups across all stages, increased macrophage presence was associated with decreased disease-free survival in patients with stage II tumors (p=0.035). Increased macrophage presence may have also correlated with decreased disease-free survival in stage IV patients, but the sample size was too small to allow detection of this difference with significance (p=0.575). Increased macrophage presence was associated with tumor microvascular invasion (p=0.0004).

Conclusion

Our results suggest that macrophage recruitment may be associated with disease progression in Wilms tumor. Quantitation of macrophage presence may therefore be a useful adjunct in refining staging algorithms for patients with stage II Wilms tumor. Such data might be useful in the effort to reduce the risk of adverse effects associated with under- or overtreatment of this neoplasm.
Appendix
Available only for authorised users
Literature
1.
go back to reference Grovas A, Fremgen A, Rauck A, Ruymann FB, Hutchinson CL, Winchester DP, Menck HR: The National Cancer Data Base report on patterns of childhood cancers in the United States. Cancer. 1997, 80 (12): 2321-2332. 10.1002/(SICI)1097-0142(19971215)80:12<2321::AID-CNCR14>3.0.CO;2-W.CrossRefPubMed Grovas A, Fremgen A, Rauck A, Ruymann FB, Hutchinson CL, Winchester DP, Menck HR: The National Cancer Data Base report on patterns of childhood cancers in the United States. Cancer. 1997, 80 (12): 2321-2332. 10.1002/(SICI)1097-0142(19971215)80:12<2321::AID-CNCR14>3.0.CO;2-W.CrossRefPubMed
2.
go back to reference Kalapurakal JA, Dome JS, Perlman EJ, Malogolowkin M, Haase GM, Grundy P, Coppes MJ: Management of Wilms' tumour: current practice and future goals. Lancet Oncol. 2004, 5 (1): 37-46. 10.1016/S1470-2045(03)01322-6.CrossRefPubMed Kalapurakal JA, Dome JS, Perlman EJ, Malogolowkin M, Haase GM, Grundy P, Coppes MJ: Management of Wilms' tumour: current practice and future goals. Lancet Oncol. 2004, 5 (1): 37-46. 10.1016/S1470-2045(03)01322-6.CrossRefPubMed
3.
go back to reference Metzger ML, Dome JS: Current therapy for Wilms' tumor. Oncologist. 2005, 10 (10): 815-826. 10.1634/theoncologist.10-10-815.CrossRefPubMed Metzger ML, Dome JS: Current therapy for Wilms' tumor. Oncologist. 2005, 10 (10): 815-826. 10.1634/theoncologist.10-10-815.CrossRefPubMed
4.
go back to reference Nakamura L, Ritchey M: Current management of wilms' tumor. Curr Urol Rep. 2010, 11 (1): 58-65. 10.1007/s11934-009-0082-z.CrossRefPubMed Nakamura L, Ritchey M: Current management of wilms' tumor. Curr Urol Rep. 2010, 11 (1): 58-65. 10.1007/s11934-009-0082-z.CrossRefPubMed
6.
go back to reference Kieran K, Anderson JR, Dome JS, Ehrlich PF, Ritchey ML, Shamberger RC, Perlman EJ, Green DM, Davidoff AM: Lymph node involvement in Wilms tumor: results from National Wilms Tumor Studies 4 and 5. J Pediatr Surg. 2012, 47 (4): 700-706. 10.1016/j.jpedsurg.2011.08.017.PubMedCentralCrossRefPubMed Kieran K, Anderson JR, Dome JS, Ehrlich PF, Ritchey ML, Shamberger RC, Perlman EJ, Green DM, Davidoff AM: Lymph node involvement in Wilms tumor: results from National Wilms Tumor Studies 4 and 5. J Pediatr Surg. 2012, 47 (4): 700-706. 10.1016/j.jpedsurg.2011.08.017.PubMedCentralCrossRefPubMed
7.
go back to reference Zhuge Y, Cheung MC, Yang R, Koniaris LG, Neville HL, Sola JE: Improved survival with lymph node sampling in Wilms tumor. J Surg Res. 2011, 167 (2): e199-e203. 10.1016/j.jss.2010.12.026.CrossRefPubMed Zhuge Y, Cheung MC, Yang R, Koniaris LG, Neville HL, Sola JE: Improved survival with lymph node sampling in Wilms tumor. J Surg Res. 2011, 167 (2): e199-e203. 10.1016/j.jss.2010.12.026.CrossRefPubMed
8.
go back to reference Raval MV, Bilimoria KY, Bentrem DJ, Stewart AK, Winchester DP, Ko CY, Reynolds M: Nodal evaluation in Wilms' tumors: analysis of the national cancer data base. Ann Surg. 2010, 251 (3): 559-565. 10.1097/SLA.0b013e3181cc95d7.CrossRefPubMed Raval MV, Bilimoria KY, Bentrem DJ, Stewart AK, Winchester DP, Ko CY, Reynolds M: Nodal evaluation in Wilms' tumors: analysis of the national cancer data base. Ann Surg. 2010, 251 (3): 559-565. 10.1097/SLA.0b013e3181cc95d7.CrossRefPubMed
9.
go back to reference Ehrlich PF, Ritchey ML, Hamilton TE, Haase GM, Ou S, Breslow N, Grundy P, Green D, Norkool P, Becker J: Quality assessment for Wilms' tumor: a report from the National Wilms' Tumor Study-5. J Pediatr Surg. 2005, 40 (1): 208-212. 10.1016/j.jpedsurg.2004.09.044. discussion 212–203CrossRefPubMed Ehrlich PF, Ritchey ML, Hamilton TE, Haase GM, Ou S, Breslow N, Grundy P, Green D, Norkool P, Becker J: Quality assessment for Wilms' tumor: a report from the National Wilms' Tumor Study-5. J Pediatr Surg. 2005, 40 (1): 208-212. 10.1016/j.jpedsurg.2004.09.044. discussion 212–203CrossRefPubMed
10.
go back to reference Qian BZ, Pollard JW: Macrophage diversity enhances tumor progression and metastasis. Cell. 2010, 141 (1): 39-51. 10.1016/j.cell.2010.03.014.CrossRefPubMed Qian BZ, Pollard JW: Macrophage diversity enhances tumor progression and metastasis. Cell. 2010, 141 (1): 39-51. 10.1016/j.cell.2010.03.014.CrossRefPubMed
11.
go back to reference Burke B, Lewis CE: The macrophage. 2002, Oxford; New York: Oxford University Press, 2 Burke B, Lewis CE: The macrophage. 2002, Oxford; New York: Oxford University Press, 2
12.
go back to reference Lewis CE, Pollard JW: Distinct role of macrophages in different tumor microenvironments. Cancer Res. 2006, 66 (2): 605-612. 10.1158/0008-5472.CAN-05-4005.CrossRefPubMed Lewis CE, Pollard JW: Distinct role of macrophages in different tumor microenvironments. Cancer Res. 2006, 66 (2): 605-612. 10.1158/0008-5472.CAN-05-4005.CrossRefPubMed
13.
go back to reference Solinas G, Germano G, Mantovani A, Allavena P: Tumor-associated macrophages (TAM) as major players of the cancer-related inflammation. J Leukoc Biol. 2009, 86 (5): 1065-1073. 10.1189/jlb.0609385.CrossRefPubMed Solinas G, Germano G, Mantovani A, Allavena P: Tumor-associated macrophages (TAM) as major players of the cancer-related inflammation. J Leukoc Biol. 2009, 86 (5): 1065-1073. 10.1189/jlb.0609385.CrossRefPubMed
14.
go back to reference Condeelis J, Pollard JW: Macrophages: obligate partners for tumor cell migration, invasion, and metastasis. Cell. 2006, 124 (2): 263-266. 10.1016/j.cell.2006.01.007.CrossRefPubMed Condeelis J, Pollard JW: Macrophages: obligate partners for tumor cell migration, invasion, and metastasis. Cell. 2006, 124 (2): 263-266. 10.1016/j.cell.2006.01.007.CrossRefPubMed
15.
go back to reference Pollard JW: Tumour-educated macrophages promote tumour progression and metastasis. Nat Rev Cancer. 2004, 4 (1): 71-78. 10.1038/nrc1256.CrossRefPubMed Pollard JW: Tumour-educated macrophages promote tumour progression and metastasis. Nat Rev Cancer. 2004, 4 (1): 71-78. 10.1038/nrc1256.CrossRefPubMed
16.
go back to reference Steidl C, Lee T, Shah SP, Farinha P, Han G, Nayar T, Delaney A, Jones SJ, Iqbal J, Weisenburger DD: Tumor-associated macrophages and survival in classic Hodgkin's lymphoma. N Engl J Med. 2010, 362 (10): 875-885. 10.1056/NEJMoa0905680.PubMedCentralCrossRefPubMed Steidl C, Lee T, Shah SP, Farinha P, Han G, Nayar T, Delaney A, Jones SJ, Iqbal J, Weisenburger DD: Tumor-associated macrophages and survival in classic Hodgkin's lymphoma. N Engl J Med. 2010, 362 (10): 875-885. 10.1056/NEJMoa0905680.PubMedCentralCrossRefPubMed
17.
go back to reference Tsutsui S, Yasuda K, Suzuki K, Tahara K, Higashi H, Era S: Macrophage infiltration and its prognostic implications in breast cancer: the relationship with VEGF expression and microvessel density. Oncol Rep. 2005, 14 (2): 425-431.PubMed Tsutsui S, Yasuda K, Suzuki K, Tahara K, Higashi H, Era S: Macrophage infiltration and its prognostic implications in breast cancer: the relationship with VEGF expression and microvessel density. Oncol Rep. 2005, 14 (2): 425-431.PubMed
18.
go back to reference Salvesen HB, Akslen LA: Significance of tumour-associated macrophages, vascular endothelial growth factor and thrombospondin-1 expression for tumour angiogenesis and prognosis in endometrial carcinomas. Int j cancer J int cancer. 1999, 84 (5): 538-543. 10.1002/(SICI)1097-0215(19991022)84:5<538::AID-IJC17>3.0.CO;2-B.CrossRef Salvesen HB, Akslen LA: Significance of tumour-associated macrophages, vascular endothelial growth factor and thrombospondin-1 expression for tumour angiogenesis and prognosis in endometrial carcinomas. Int j cancer J int cancer. 1999, 84 (5): 538-543. 10.1002/(SICI)1097-0215(19991022)84:5<538::AID-IJC17>3.0.CO;2-B.CrossRef
19.
go back to reference Hamada I, Kato M, Yamasaki T, Iwabuchi K, Watanabe T, Yamada T, Itoyama S, Ito H, Okada K: Clinical effects of tumor-associated macrophages and dendritic cells on renal cell carcinoma. Anticancer Res. 2002, 22 (6C): 4281-4284.PubMed Hamada I, Kato M, Yamasaki T, Iwabuchi K, Watanabe T, Yamada T, Itoyama S, Ito H, Okada K: Clinical effects of tumor-associated macrophages and dendritic cells on renal cell carcinoma. Anticancer Res. 2002, 22 (6C): 4281-4284.PubMed
20.
go back to reference Ryder M, Ghossein RA, Ricarte-Filho JC, Knauf JA, Fagin JA: Increased density of tumor-associated macrophages is associated with decreased survival in advanced thyroid cancer. Endocr Relat Cancer. 2008, 15 (4): 1069-1074. 10.1677/ERC-08-0036.PubMedCentralCrossRefPubMed Ryder M, Ghossein RA, Ricarte-Filho JC, Knauf JA, Fagin JA: Increased density of tumor-associated macrophages is associated with decreased survival in advanced thyroid cancer. Endocr Relat Cancer. 2008, 15 (4): 1069-1074. 10.1677/ERC-08-0036.PubMedCentralCrossRefPubMed
21.
go back to reference Lin EY, Nguyen AV, Russell RG, Pollard JW: Colony-stimulating factor 1 promotes progression of mammary tumors to malignancy. J Exp Med. 2001, 193 (6): 727-740. 10.1084/jem.193.6.727.PubMedCentralCrossRefPubMed Lin EY, Nguyen AV, Russell RG, Pollard JW: Colony-stimulating factor 1 promotes progression of mammary tumors to malignancy. J Exp Med. 2001, 193 (6): 727-740. 10.1084/jem.193.6.727.PubMedCentralCrossRefPubMed
22.
go back to reference Harris JA, Jain S, Ren Q, Zarineh A, Liu C, Ibrahim S: CD163 versus CD68 in tumor associated macrophages of classical Hodgkin lymphoma. Diagn Pathol. 2012, 7: 12-10.1186/1746-1596-7-12.PubMedCentralCrossRefPubMed Harris JA, Jain S, Ren Q, Zarineh A, Liu C, Ibrahim S: CD163 versus CD68 in tumor associated macrophages of classical Hodgkin lymphoma. Diagn Pathol. 2012, 7: 12-10.1186/1746-1596-7-12.PubMedCentralCrossRefPubMed
23.
go back to reference Chen JJ, Lin YC, Yao PL, Yuan A, Chen HY, Shun CT, Tsai MF, Chen CH, Yang PC: Tumor-associated macrophages: the double-edged sword in cancer progression. J Clin Oncol Official J Ame Soc Clin Oncol. 2005, 23 (5): 953-964.CrossRef Chen JJ, Lin YC, Yao PL, Yuan A, Chen HY, Shun CT, Tsai MF, Chen CH, Yang PC: Tumor-associated macrophages: the double-edged sword in cancer progression. J Clin Oncol Official J Ame Soc Clin Oncol. 2005, 23 (5): 953-964.CrossRef
24.
go back to reference Allavena P, Mantovani A: Immunology in the clinic review series; focus on cancer: tumour-associated macrophages: undisputed stars of the inflammatory tumour microenvironment. Clin Exp Immunol. 2012, 167 (2): 195-205. 10.1111/j.1365-2249.2011.04515.x.PubMedCentralCrossRefPubMed Allavena P, Mantovani A: Immunology in the clinic review series; focus on cancer: tumour-associated macrophages: undisputed stars of the inflammatory tumour microenvironment. Clin Exp Immunol. 2012, 167 (2): 195-205. 10.1111/j.1365-2249.2011.04515.x.PubMedCentralCrossRefPubMed
Metadata
Title
Correlation of tumor-associated macrophages and clinicopathological factors in Wilms tumor
Authors
Peter Liou
Leah Bader
Antai Wang
Darrell Yamashiro
Jessica J Kandel
Publication date
01-12-2013
Publisher
BioMed Central
Published in
Vascular Cell / Issue 1/2013
Electronic ISSN: 2045-824X
DOI
https://doi.org/10.1186/2045-824X-5-5

Other articles of this Issue 1/2013

Vascular Cell 1/2013 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.